Pivotal China leads $16.5m seed round in biopharma firm Oncologie

Pivotal China leads $16.5m seed round in biopharma firm Oncologie

Oncologie's global team. Photo from company's website.

Chinese life sciences venture capital fund Pivotal bioVenture Partners China (Pivotal China) has led the $16.5-million seed funding round in Oncologie, a Boston- and Shanghai-headquartered biopharmaceutical company that targets cancer patients.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter